PRECIGEN, INC. (PGEN) is held by 1 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 1 fund adding versus the previous quarter. Insiders were net sellers over the last 90 days ($24.7K bought vs $2.3M sold). Latest close $4.27 as of Nov 18, 2026.
Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: Aug 26, 2026 · Congress to Nov 16, 2026.
Patient Capital Management — 1 tracked fund hold PGEN. See all holders.
Insiders bought on the open market (1 purchase, $24.7K) vs 4 sales ($2.3M). Latest buy: Aug 21, 2026. Insider trading
Merck & Co., Inc. (MRK) · ELI LILLY & Co (LLY) · PFIZER INC (PFE) · AbbVie Inc. (ABBV) · BRISTOL MYERS SQUIBB CO (BMY) — stocks the same funds also hold. See all related stocks.
| Fund | Portfolio weight | Shares | Change vs prev. quarter |
|---|---|---|---|
| Patient Capital Management | 3.56% | 19,036,976 | ADDED (+6.8%) Q3 filed Nov 12 |
Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.
Price change since quarter-end: -18.3% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.
Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.
Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.
| Institutions holding | 210 of 8,857 filers |
| Long-only filers among them | 209 |
| Change vs 2026 Q1 | +13 net · 204 entered · 191 exited |
| Shares reported, all filers | 140,105,116 |
| Reported value, all filers | $822.1M |
Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations (SIC 2834) |
| Revenue · FY2025 | $9.7M |
| Net income · FY2025 | $-250.6M |
| Total assets · FY2025 | $155.5M |
| Shares outstanding | 358,035,247 |
| Market cap (at latest close) | $1.5B |
Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Jul 31, 2026.
| Shares short · Oct 15, 2026 | 46,390,144 |
| Share of shares outstanding | 12.96% |
| Days to cover | 10.21 |
Shares short at recent settlements — Jul 31, 2026: 42.0M · Aug 14, 2026: 42.2M · Aug 31, 2026: 42.2M · Sep 15, 2026: 42.3M · Sep 30, 2026: 47.5M · Oct 15, 2026: 46.4M.
Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Jul 31, 2026.
| Shares failed to deliver · Oct 14, 2026 | 0 |
| Share of shares outstanding | 0.00% |
| Fails as a share of short interest · Oct 15, 2026 | 0.0% |
Fails to deliver at recent settlements — Jul 31, 2026: 0 · Aug 14, 2026: 1K · Aug 31, 2026: 4 · Sep 15, 2026: 0 · Sep 30, 2026: 309 · Oct 14, 2026: 0.
Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Jul 31, 2026.
1 insider bought on the open market in the last 90 days (1 purchase, $24.7K), against 4 sales by 3 insiders ($2.3M). Latest buy: Aug 21, 2026.
Source: SEC Form 4 filings. Open-market transactions only.
| Latest open-market buy | Transaction price | Price change since disclosure |
|---|---|---|
| AGEE NANCY H · 3,411 shares on Aug 21, 2026 · filed Aug 25, 2026 | $7.23 | -42.2% (close Aug 26, 2026 → Nov 17, 2026) |
Reference close is the first trading day after the filing (Aug 26, 2026). The transaction price is what the insider paid; the price change is on closing prices (dividends excluded).
Recent open-market trades
| Date | Insider | Role | Buy / Sell | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Aug 26, 2026 | KINDLER JEFFREY B | Sell | 185,000 | $7.44 | $1.4M | SEC filing | |
| Aug 25, 2026 | Shah Rutul R | Chief Operating Officer | Sell | 15,342 | $7.50 | $115.1K | SEC filing |
| Aug 25, 2026 | Tennant Phil | Chief Commercial Officer | Sell | 79,166 | $7.50 | $593.7K | SEC filing |
| Aug 21, 2026 | AGEE NANCY H | Buy | 3,411 | $7.23 | $24.7K | SEC filing | |
| Aug 21, 2026 | Shah Rutul R | Chief Operating Officer | Sell | 34,658 | $7.50 | $259.9K | SEC filing |
Most recent open-market transactions in the same 90-day window, most recent first. Source: SEC Form 4 filings.
| Filed | Seller | Role | Shares to sell | Market value | Approx. sale date | Source |
|---|---|---|---|---|---|---|
| Aug 26, 2026 | Jeffrey Kindler | Director | 185,000 | $1.4M | Aug 26, 2026 | SEC filing |
| Aug 25, 2026 | Shah Rutul R | Officer | 15,342 | $115.1K | Aug 25, 2026 | SEC filing |
| Aug 25, 2026 | Tennant Phil | Officer | 79,166 | $593.7K | Aug 25, 2026 | SEC filing |
| Aug 21, 2026 | Shah Rutul R | Officer | 34,658 | $259.9K | Aug 21, 2026 | SEC filing |
| Aug 6, 2026 | Shah Rutul R | Officer | 32,739 | $224.6K | Aug 6, 2026 | SEC filing |
| Aug 3, 2026 | Shah Rutul R | Officer | 33,772 | $219.5K | Aug 3, 2026 | SEC filing |
| Jul 31, 2026 | Thomasian Harry Jr. | Officer | 100,000 | $605.6K | Jul 31, 2026 | SEC filing |
| Jul 1, 2026 | Thomasian Harry Jr. | Officer | 171,429 | $948.5K | Jul 1, 2026 | SEC filing |
| Jun 29, 2026 | Sabzevari Helen | Officer, Director | 346,836 | $2.0M | Jun 29, 2026 | SEC filing |
| Jun 29, 2026 | Shah Rutul R | Officer | 42,924 | $251.1K | Jun 29, 2026 | SEC filing |
A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.
| Filed | Form | Price change since disclosure |
|---|---|---|
| Mar 31, 2026 | SCHEDULE 13D/A | +9.2% (close Apr 1, 2026 → Nov 17, 2026) |
Reference close is the first trading day after the filing (Apr 1, 2026). A Schedule 13D reports beneficial ownership, not a purchase — there is no transaction price to show. Source: SEC EDGAR Schedule 13D filings.
| Filed | Filer | Form | Shares | % owned | Event date | Source |
|---|---|---|---|---|---|---|
| Aug 7, 2026 | Ares Trading SA | SC 13G/A | 17,467,152 | 4.9% | Jun 9, 2026 | SEC filing |
| May 15, 2026 | Point72 Asset Management, L.P. | SC 13G/A | 6,741,861 | 1.9% | Mar 31, 2026 | SEC filing |
| Mar 31, 2026 | RANDAL J. KIRK | SC 13D/A | 133,956,416 | 35.9% | Mar 30, 2026 | SEC filing |
| Feb 13, 2026 | Patient Capital Management, LLC | SC 13G/A | 36,006,800 | 10.2% | Dec 31, 2025 | SEC filing |
| Jan 23, 2026 | Point72 Asset Management, L.P. | SC 13G | 18,383,242 | 5.2% | Jan 22, 2026 | SEC filing |
| Nov 21, 2025 | RANDAL J. KIRK | SC 13D/A | 141,519,399 | 38.1% | Nov 19, 2025 | SEC filing |
| Oct 30, 2025 | Patient Capital Management, LLC | SC 13G/A | 45,223,463 | 13.6% | Dec 31, 2024 | SEC filing |
| Sep 23, 2025 | William H. Miller III Living Trust dated April 17, 2017 | SC 13G | 34,051,925 | 9.2% | Jun 26, 2025 | SEC filing |
| Sep 19, 2025 | RANDAL J. KIRK | SC 13D/A | 146,295,359 | 39.4% | Sep 17, 2025 | SEC filing |
| Feb 12, 2025 | Patient Capital Management, LLC | SC 13G/A | 17,683,758 | 6.5% | Dec 31, 2024 | SEC filing |
One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.
Data unavailable — no congressional STOCK Act transactions for this ticker were parsed in the current window (as of Nov 16, 2026).
Industry: Pharmaceutical Preparations (SIC 2834). Standing committees with jurisdiction over this industry: Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce.
None of the members who traded this stock in the current window sit on these committees.
Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.
Lobbying: 13 Lobbying Disclosure Act filings named this company as client, 2017–2020; most common issues: Trade (domestic/foreign) (9), Agriculture (8), Energy/Nuclear (3).
Federal contracts: no obligated amounts found for this ticker (USASpending, fiscal years 2021–2026).
Lobbying filings are matched by company core name; a filing can match more than one ticker. Contract amounts are obligated amounts (money committed, not money spent), matched by recipient name — contracts under a subsidiary’s name can be missed. Sources: Senate Lobbying Disclosure Act filings; USAspending.gov. See Methodology.
Red Flags
· Distress Risk (Altman Z″) — Altman Z″-Score below 1.10
· Excess Accruals (Sloan) — Sloan accruals ratio beyond ±25%
Key figures
· Distress Risk (Altman Z″) — Z″-Score: -50.41 · Working capital / assets: 0.50 · Retained earnings / assets: -15.06 · EBIT / assets: -0.71 · Equity / liabilities: 0.16
· Excess Accruals (Sloan) — Accruals ratio: -103.7% · Net income: $-250.6M · Operating cash flow: $-87.8M · Investing cash flow: $-1.5M
Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.
· Insider BEST — appeared in 5 of the last 20 quarterly lists; latest 2025 Q3, ranked #25 of 50.
| 13F signal (2021 Q3 – 2026 Q1) | Events | Win rate | Avg return | SPY | Excess |
|---|---|---|---|---|---|
| Share count tripled (3x) | 1 | 0.0% | -30.7% | +1.9% | -32.6% |
Measured from SEC 13F filings: entry at the close on the first trading day after each quarter’s filing deadline, exit one quarter later on the same rule, dividend-adjusted closes. Past records do not guarantee future results — see Track Record and Methodology.
Also held by the tracked funds that hold PGEN — ranked by lift, the co-holding pattern described in Methodology: Merck & Co., Inc. (MRK) · ELI LILLY & Co (LLY) · PFIZER INC (PFE) · AbbVie Inc. (ABBV) · BRISTOL MYERS SQUIBB CO (BMY) · ASTRAZENECA PLC (AZN) · ABBOTT LABORATORIES (ABT) · NOVARTIS AG (NVS).
8 of the 8 are same-industry (SIC) fillers: fewer than 4 stocks met the lift rule for this stock.
| Filed | Items | Source |
|---|---|---|
| Nov 5, 2026 | 2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits | SEC filing |
| Aug 4, 2026 | 2.02 Results of Operations and Financial Condition | SEC filing |
| Jun 24, 2026 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers · 5.07 Submission of Matters to a Vote of Security Holders · 9.01 Financial Statements and Exhibits | SEC filing |
Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.
Merck & Co., Inc. (MRK) · Track Record: how the signals scored · Practice timing on PGEN
One email a week: the week’s new filings and research. Subscribe free
Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.